Mobile website
Archive > Volume 22 Issue 4 > 2015,22(4):509-513. DOI:10.3872/j.issn.1007-385X.2015.04.018 Prev Next
Clinical Research
Efficacy of the combined therapy with autologous dendritic cells-cytokine induced killer cells and percutaneous microwave coagulation for hepatocellular carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective : To evaluate the clinical efficacy of combined therapy using autologous dendritic cells-cytokine induced killer cells (DC-CIK) and percutaneous microwave coagulation (PMCT) in the treatment of hepatocellular carcinoma. Methods: Forty four patients with hepatocellular carcinoma treated with PMCT and DC-CIK (combination group) and 44 patients treated with PMCT alone (control group) were enrolled in the Department of Biotherapy of Eastern Hepatobiliary Surgical Hospital from January 2012 to February 2014. For patients in the combination group, peripheral blood mononuclear cells (PBMCs) were isolated on day 1 and PMCT were performed on the second day. After a ten day-culture, the DC-CIK cells were generated and transfused back to patients together with intradermal injection of DC vaccine. The second and third course of DC-CIK therapy were given one month and two months later respectively. The AFP level, immune function, progression-free survival, overall survival, and adverse effects were assessed for all the patients. Results: Although the level of AFP and regulatory T cells in peripheral blood decreased in the patients of both groups, their decline in the combination group was significantly more than that of the control group (P<0.05). Compared with that of pre-treatment, the lymphocyte number and subpopulations didn’t change significantly in the control group (P>0.05), but they did increase markedly in the combination group (P<0.05). The median progression-free survival and median overall survival were both increased in the combination group compared with that of the control group (7.1 m vs 4.9 m, 215 m vs 14.0 m, P<0.05). Conclusion: Adoptive transfer of autologous DC-CIK in combination with PMCT is an effective treatment for patients with hepatocellular carcinoma. It improves the immune function, postpones the recurrence of tumor, and prolongs the overall survival with acceptable toxicities.
Keywords:
Project Supported:
Project supported by the National Key Science and Technology Program of China (No. 2013ZX09102-060; No. 2013ZX10002-010-007; No. 2012ZX0002-014-005)
Clc Number:
